About this item:

166 Views | 84 Downloads

Author Notes:

Corresponding author: Mingzhen, Zhang, Ph.D., Center for Diagnostics and Therapeutics, Institute for Biomedical Science, Georgia State University, Atlanta, 30303, USA Telephone: +1 (404) 413 3597, Fax: +1 (404) 413 3580, mzhang21@gsu.edu

Subject:

Research Funding:

This work was supported by the National Institutes of Health of Diabetes and Digestive and Kidney (RO1-DK-071594 to D.M) and Crohn’s & Colitis Foundation of America (ID: 369809 to M.Z. Z).

Keywords:

  • Science & Technology
  • Technology
  • Engineering, Biomedical
  • Materials Science, Biomaterials
  • Engineering
  • Materials Science
  • Edible ginger derived nanoparticles
  • Inflammatory bowel disease
  • Colitis-associated cancer
  • Natural drug delivery system
  • Therapy
  • EXOSOME-LIKE NANOPARTICLES
  • CHRONIC INTESTINAL INFLAMMATION
  • COLORECTAL-CANCER
  • COLON-CANCER
  • ULCERATIVE-COLITIS
  • T-CELLS
  • BARRIER FUNCTION
  • POLYMERIC NANOPARTICLES
  • LOADED NANOPARTICLES
  • PROSTATE-CANCER

Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer

Show all authors Show less authors

Tools:

Journal Title:

Biomaterials

Volume:

Volume 101

Publisher:

, Pages 321-340

Type of Work:

Article | Post-print: After Peer Review

Abstract:

There is a clinical need for new, more effective treatments for chronic and debilitating inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In this study, we characterized a specific population of nanoparticles derived from edible ginger (GDNPs 2) and demonstrated their efficient colon targeting following oral administration. GDNPs 2 had an average size of ~230 nm and exhibited a negative zeta potential. These nanoparticles contained high levels of lipids, a few proteins, ~125 microRNAs (miRNAs), and large amounts of ginger bioactive constituents (6-gingerol and 6-shogaol). We also demonstrated that GDNPs 2 were mainly taken up by intestinal epithelial cells (IECs) and macrophages, and were nontoxic. Using different mouse colitis models, we showed that GDNPs 2 reduced acute colitis, enhanced intestinal repair, and prevented chronic colitis and colitis-associated cancer (CAC). 2D-DIGE/MS analyses further identified molecular target candidates of GDNPs 2 involved in these mouse models. Oral administration of GDNPs 2 increased the survival and proliferation of IECs and reduced the pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β), and increased the anti-inflammatory cytokines (IL-10 and IL-22) in colitis models, suggesting that GDNPs 2 has the potential to attenuate damaging factors while promoting the healing effect. In conclusion, GDNPs 2, nanoparticles derived from edible ginger, represent a novel, natural delivery mechanism for improving IBD prevention and treatment with an added benefit of overcoming limitations such as potential toxicity and limited production scale that are common with synthetic nanoparticles.

Copyright information:

© 2016 Elsevier Ltd.

Export to EndNote